Computational Repurposing of FDA Approved Drugs Against Cyclin Dependent Kinase (CDK2)
- 1Biotecnika Info Labs Pvt Ltd
Abstract
Drug repurposing is an approach for identifying new therapeutic with existing FDA approved drugs. Cyclin-dependent kinase 2 (CDK2) is an important regulator of cell cycle progression. The present study aimed to identify FDA-approved drugs with potential binding activity against CDK2 using a Computational drug-repurposing approach. The crystal structure of Human CDK2 (PDB ID: 3PY0) was used for Molecular docking, followed by Protein Ligand Interaction Profiler (PLIP) analysis to evaluate Protein Ligand interactions. Further for drug-likeness and pharmacokinetic properties using Swiss ADME and for Predicted toxicity using ProTox Was done. Based on this docking affinity, interaction profiles, drug-likeness, pharmacokinetics and toxicity, the best target was selected. Carteolol demonstrated the most balanced overall computational profile and was selected as the primary candidate for potential computational finding to provide repurposing against CDK2. Experimental studies are required to validate its direct binding and inhibitory activity against CDK2.
Related
- Machine Learning and Virtual Screening Methods to Discover Potential Cyclin-Dependent Kinase 2 (CDK2) Inhibitors
- Interpreting Graph Neural Networks for Antibacterial Drug Repurposing against Acinetobacter baumannii
- Repurposing clofarabine against enteric pathogens via metabolic starvation
- Repurposing amlodipine, fluoxetine, and escitalopram as non-antibiotic adjuvants: in vitro enhancement of ciprofloxacin and fluconazole activity against multidrug-resistant bacterial and candida clinical isolates.
- Benchmarking interface confidence as a selection criterion for computational nanobody design against survivin's BIR-domain groove
BibTeX
@misc{deevi2026computational,
title = {{Computational Repurposing of FDA Approved Drugs Against Cyclin Dependent Kinase (CDK2)}},
author = {G. Deevi and B. Singh},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.27.762194},
url = {https://www.biorxiv.org/content/10.64898/2026.10.27.762194v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Computational Repurposing of FDA Approved Drugs Against Cyclin Dependent Kinase (CDK2)
AU - G. Deevi
AU - B. Singh
PY - 2026
DA - 2026/10/27
PB - bioRxiv
DO - 10.64898/2026.10.27.762194
UR - https://www.biorxiv.org/content/10.64898/2026.10.27.762194v1
AB - Drug repurposing is an approach for identifying new therapeutic with existing FDA approved drugs. Cyclin-dependent kinase 2 (CDK2) is an important regulator of cell cycle progression. The present study aimed to identify FDA-approved drugs with potential binding activity against CDK2 using a Computational drug-repurposing approach. The crystal structure of Human CDK2 (PDB ID: 3PY0) was used for Molecular docking, followed by Protein Ligand Interaction Profiler (PLIP) analysis to evaluate Protein Ligand interactions. Further for drug-likeness and pharmacokinetic properties using Swiss ADME and for Predicted toxicity using ProTox Was done. Based on this docking affinity, interaction profiles, drug-likeness, pharmacokinetics and toxicity, the best target was selected. Carteolol demonstrated the most balanced overall computational profile and was selected as the primary candidate for potential computational finding to provide repurposing against CDK2. Experimental studies are required to validate its direct binding and inhibitory activity against CDK2.
ER -